Artbio brings in $90M for radioactive molecules that target cancer


A four-year-old Boston startup is getting $90 million to help develop radioactive molecules that target cancer tumors.

Previous Novant Health files building permits for $130M expansion of Matthews Medical Center
Next Greater Louisville Inc., Humana Foundation pair up on grant awards to boost mental health access